Humira (Rheumatoid Arthritis) Forecast and Market Analysis
GlobalData has released its new PharmaPoint Drug Evaluation report, Humira (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lillys anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZs SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market. Humira is a recombinant human IgG1 monoclonal antibody (mAb) which binds to TNF-alpha and blocks interaction with p55 and p75 cell-surface receptors; this blockage reduces inflammation and stops tissue destruction. It was the first fully humanized mAb TNF inhibitor to enter the market for the treatment of RA. In 2012, pharmaceutical industry analysts estimate that Humira will be the worlds top-selling medicine at $9 billion in sales.
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Humira including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Humira for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Humira performance
- Obtain sales forecast for Humira from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)